Oligo Medic is a privately held Canadian company created in 2010 and focused on developing and commercializing medical devices.

Oligo Medic's founders are biomaterials experts who have developed several devices for the orthopedic market.

Oligo Medic's technology is based on injectable thermosensitive hydrogels (thermogels) that solidify at body-temperature.

Oligo Medic's leading product JointRep™ is CE-marked, and patented and granted in all major countries.

JointRep™ is presently distributed to the orthopedic market to repair cartilage, with spectacular success in over 2000 patients.

JointRep™ can also be used to deliver platelet rich plasma (PRP) or adipose derived mesenchymal stem cells for various orthopedic applications such as tendon and meniscus treatment.

Controlled post-market clinical study for use of JointRep™ in conjunction with microfracture in grade III-IV knee cartilage lesions showed exceptional results in terms of pain reduction and mobility improvement for patients, and MRI evidence of hyaline cartilage regrowth.

JointRep™ - Cartilage Regeneration Technology

JointRep™ is an injectable implant. It is the first product to provide a minimally invasive curative treatment for traumatic or arthrosis cartilage defects of any size or grade. Established treatments at best alleviate pain and delay the progression of cartilage loss. Heavier alternatives include total joint replacement.

JointRep™ is being tested in a controlled clinical study in Europe, to compare a JointRep™ + microfracture operation to an operation with standard microfracture alone, on 69 patients of ages 18-75 with grade III-IV cartilage lesions unrestricted in size.

The patients had to follow a moderate two week rehab protocol, in contrast to a stringent 8 week rehab protocol in conventional microfracture.

The results reported through WOMAC scores indicate near-elimination of symptoms at 6 and 12 months in the groups treated with JointRep™ (right columns in the diagram on the left).

These results are substantiated with MRI evidence of genuine hyaline cartilage regrowth.

  • JointRep™ is a thermosensitive bioadhesive hydrogel that rapidly solidifies when heated to body temperature. It is applied directly onto cartilage lesions and sticks firmly. It provides a scaffold matrix for chondrocyte proliferation following microfracture.
  • JointRep™ is administered in a one-step procedure as part of a standard arthroscopy, adding only a few minutes to the operation.
  • The operation is performed under local anesthesia and the patient is released the same day and allowed total load ambulation with contralateral crutch after 90 minutes.
  • JointRep™ can be applied to lesions of any size or shape in any joint.


JointRep™ applied following microfracture (animation + audio).

JointRepTM is mixed in the surgical theatre in a few moments.

  • No technical hurdles: JointRep™ should be stored between 2 and 8°C, but can be transported at ambient temperature.
  • Can be used without planning. Preparation time is between 3 and 5 minutes, enabling the physician to use it ad-hoc if defects are noticed in the course of a routine arthroscopic inspection or treatment (a study of over 30,000 arthroscopies in the United States has revealed an average of 2.7 defects in 63% of patients).
  • Unlike a viscosupplement, JointRep™ directly repairs affected cartilage.
  • JointRep™ is currently not licenced for sale in the USA and Canada.

Second look arthroscopy: cartilage regrown with JointRep™ is practically indistinguishable after 6 months from healthy pre-existing cartilage.

From left to right:

Defect in intercondylar notch prepared for JointRep™.   Defect filled with material.  Defect one year after.
1.Healthy cartilage 2.Defect.

Video Gallery

Arthroscopic lavage/debridement operation with JointRep™

This procedure is used to treat less severe chondropathies like symptomatic grade I-II osteoarthritis. There is no cartilage regrowth but lasting pain relief after 2-3 months. The age limit is 55.

With Dr. Nicolas Duval, Orthopedist


Standard Arthroscopic operation (Lavage/debridement)


Preparation and injection of JointRep™ implant


Arthroscopic JointRep™ operation with microfracture

This procedure is used to treat more severe chondropathies like grade III-IV osteoarthritis. The rehab period is very short, the pain relief is very quick and there is genuine regrowth of hyaline cartilage. The age limit is 75.

With Dr. Gennaro Pipino, full professor of orthopedic surgery, University of Lugano (Switzerland)


View from the operation room


Operation screen


Total weight ambulation with contralateral cane


90 minutes after the operation.

Demo: mixing JointRep™ components


Patients

One month after knee osteoarthritis treatment with microfracture + JointRep™.


A happy patient's post to Facebook three weeks after his microfracture + JointRep™.


News and Updates

2017
Other clinical trials on different indications are planned and will be disclosed when protocols are defined.

2017
Preliminary steps taken toward procedures with FDA for market approval in the US.

2016
Gaining market penetration in Europe, ANZ regions, Middle East, South East Asia, Central and South America including Brazil.

2015
European controlled clinical trial: 69 patients, and comparing microfracture to microfracture & JointRep™. First study results will be published during Winter-2016.

2014
Initial experimentation with JointRep™ and microfracture. Results are highly favorable with fast pain relief, accelerated recovery time, and nice cartilage regrowth.
2013
Structured OligoMedic for strategic partnership and initiated clinical trials and post market evaluation.
2012
Manufacturing, packaging, and shipping (at ambient temperature!) processes defined. Obtained CE mark in October.

2011
Follow up pre-clinical study on Health Canada SAP.

2010
Creation of Oligo Medic Inc. Development of technology platform. Bench testing and pre-clinical characterization. Initiated Health Canada Special Access Program ("SAP"). Successful first-in-man JointRep™ operation. 

We succeeded in premixing JointRep™ with platelet rich plasma (PRP) while maintaining all the product's properties. The same can be done with bone marrow extract. This opens the possibility of using JointRep™ to deliver PRP or adipose derived mesenchymal cells for various orthopedic applications such as tendon and meniscus treatment.

 


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of PRP (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

 


Video showing the mixing of B1 and B2 first, then the mixing of (B1+B2) with approximately 1 cc of bone marrow extract (or less) and finally the mixing of (B1+B2+ PRP) and A giving an injectable gel that solidifies with temperature as does JointRep™ alone.

Management Team

Dr. Amine Selmani, PhD

Executive Chairman
Dr. Amine Selmani holds a PhD in Material Sciences (1985) from the University of Montreal. After three years as post-doc positions in different universities, he joined the prestigious engineering school ‘Ecole Polytechnique de Montreal’ as a Professor. Dr. Selmani’s research in biomaterials and biotechnologies led him to incorporate BioSyntech in 1995 and be part of its executive team as CEO and Chairman of the Board for close to 10 years (1995-2004). During his tenure, Dr. Selmani was able to take this biotechnology company public on both Nasdaq and TSX.

More…

Also, Dr. Selmani founded in 1992 POLNOR (Polytechnique-Noranda) group of around 30 engineers and professionals, with the mandateto provide higher value to the Noranda amorphous silicon and other products (produced in very small quantities). Big budgets coming from Noranda, Natural Sciences and Engineering Research Council of Canada, 3M and The Ecole Polytechnique de Montreal allowed the development of High Resolution Digital Mamograph X-rays plates that are today used in most of radiology centers and commercialized by the well-known company in the field, Analogic. Few employees coming from the same project created a company (5N Plus), now leader in the world of high-specialized materials. The company is listed on the TSX, Toronto.

Jerett Creed

Chief Executive Officer
Mr. Creed has more than 20 years of medtech experience spanning multiple disease sectors and leadership roles with a strong focus on international commercialization, capital markets and business development. Mr. Creed has participated in a leadership role on transactions exceeding $650 million in M&A activity including 2 public offerings. Most recently Mr. Creed was in charge of launching Oligo Medic's JointRep™ product throughout Latin America. Prior to that, Mr. Creed was founder and CEO of Cardigant Medical, a formerly public company focused on the development and commercialization of novel peptide mimetics for treating vascular disease. Before that Mr. Creed was interim Chief Financial Officer for a publicly traded oil and gas company providing leadership through multiple acquisitions and one divestiture. Mr. Creed began his career with Johnson and Johnson initially focused on manufacturing and product development of early angioplasty balloons and bare metal stents ultimately spending more than a decade with the company finishing his tenure as Director of Business Development for an internally funded stem cell based incubator. Mr. Creed holds a Master of Science degree in Accounting and a Bachelor of Science degree in Engineering both from the University of Miami.

Dr. Abdellatif Chenite, PhD

Chief Technology Officer
Dr Chenite has the distinction of being co-founder of Oligo Medic and inventor of its technology platform.  He successfully led the first company product from conception through to manufacturing completion. Dr Chenite is an accomplished scientist and inventor, with many patents and relevant publications, focused on the development of innovative biomaterial devices for biomedical technologies. His impressive array of knowledge and technology skills is a real asset for the company.

More…

Dr Chenite obtained a Ph.D. in Polymer Chemistry, in1992, from the University of Montréal, and immediately after his graduation he was hired a Research Associate at the National Research Council, in Ottawa, Canada, where he worked during 3 years. In 1996, he joined Biosyntech as research director and he was an essential contribution to the company success by inventing BST-Gel technology platform early in 1998. He has published more than 35 peer-reviewed scientific articles and authored patent applications for numerous distinct inventions.

Monique Jarry

VP Finance & Corporate Development
Mrs. Monique Jarry
VP Finance & Corporate Development

Ms Jarry holds a BA and MA (1991) from University of Montreal. She implemented many accounting systems in public companies listed in Nasdaq BB and on TSX. Ms. Jarry supervised all the financial aspects of a private investment company from 1992 until 2010, when she joined Oligomedic as a VP Finances.

Dr. Cyril Chaput, PhD, MBA

VP RA/QA
Cyril Chaput, PhD, MBA,has more than 15 years of experience as a manager in Life Science and Biotechnological companies. Cyril Chaput has biomedical engineering and biomaterials background, and holds several patents and scientific publications. He has been involved in R&D, intellectual property management, product management and business development in various Biotech and medical technology companies.

More…

Cyril Chaput has been involved in the Biomaterial platforms development at Bio Syntech Canada, and has been IP and Business Development manager and Product manager for the Medical Device company, Angiogene Inc. In addition to his extensive work experience, Mr. Chaput holds a PhD in biomedical engineering from the EcolePolytechnique de Montreal, and a MBA in Bio-industries Management from the UQAM in Canada.

Sam Alexandre Selmani

VP International Markets

Dr. Yves De Backer

Europe (CE) representative
Yves de Backer brings more than 25 years of Research, Development, sales development and Regulatory Affairs experience in biomaterials and implanted medical devices. His regulatory submissions experience includes CE Mark, FDA 510k, and PMA/IDE. As Founder and President of Bio-Consulting international, he has managed multiple regulatory and clinical investigation submissions from protocol development, investigator selection/management, and quality audits.

More…

More than 50 firms have been advised during his consultancy services including J&J Depuy, Cervitech Spine, and SanofiAvantis FOVEA. Yves is also the MedTech advisor for SEVENTURE, a European VC expert in Biomedical, Medtech and Biotech investment.
Prior to founding Bio-Consulting, Yves served as Director of Biomaterials at Medtronic Sofamor, and as Project Manager, Biomaterials for Zimmer Europe. Yves is a guest lecturer on biomaterials regulation at Paris Lariboisière Medical University and Lausanne Polytechnicum University. He received a Ph.D. in pharmaceutical sciences from Lille Pharma University, and a MSc. in biochemistry from Lille Sciences University.
Yves has a great knowledge of European market and, KOL’s, and has experience with European distributors in orthobiologics and arthroscopy.During his career he launched and develop several biomaterials for bone repair in spine, knee arthroscopy and extremities.

Contact us

Don’t hes­i­tate to con­tact us for any enquiries you might have.

500 Cartier Blvd. № 113, Laval

(+1) 450-680-3371

info@oligomedic.com

Your Name (required)

Your Email (required)

Subject

Your Message